title: Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease.
abstract: BACKGROUND
  Aspirin-exacerbated respiratory disease (AERD) is a chronic illness of progressive recurrent sinus disease with nasal polyps and asthma. No population-based comprehensive surveys of patients with AERD have been carried out to assess specific quality-of-life impact or perceptions of treatment benefit.
  
  
  OBJECTIVE
  This survey analyzed perceptions and quality of life in those living with AERD and queried patient observations of treatment effectiveness. The survey assessed whether dietary and nutritional support was used to manage AERD, and if so, whether there was a perceived benefit.
  
  
  METHODS
  This survey was publicized through clinics that treat patients with AERD, Web sites, and online blogs.
  
  
  RESULTS
  Results are reported for 190 patients. Most subjects reported an adverse effect of AERD on quality of life. Chronic nasal symptoms followed by decreased sense of smell were reported to have the greatest impact on quality of life—in 81 (43%) and 74 (39%), respectively. Those who lost their ability to smell (n = 65; 34%) reported that they missed the enjoyment of food and eating the most. A minority indicated that a combination of medications (aspirin, leukotriene receptor antagonist, zileuton, or omalizumab) was more effective than 1 alone. Of those surveyed, 120 (63%) respondents felt that components of their diet contributed to their disease and 147 (77%) respondents reported having reactions after alcohol consumption.
  
  
  CONCLUSIONS
  Patients with AERD live with frustration and report a poor quality of life in spite of several pharmacologic treatments including aspirin desensitization followed by daily aspirin. Despite ongoing medical therapy, the burden of disease in AERD remains high.
authors: Scripps Clinic, San Diego, Calif. Electronic address: ta.von@scrippshealth.org.
authors: Von
authors: V
authors: Ta
authors: Scripps Clinic, San Diego, Calif.
authors: Andrew A
authors: AA
authors: White
mesh_terms: D000328:Adult; D000428:Alcohol Drinking / Q000009:adverse effects; D000485:Allergens / Q000276:immunology; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D055963:Asthma, Aspirin-Induced / Q000175:diagnosis* / Q000628:therapy; D002908:Chronic Disease; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009298:Nasal Polyps / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D000069444:Omalizumab / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D000485:Allergens; D000069444:Omalizumab; D001241:Aspirin; C063449:zileuton; D006918:Hydroxyurea
keywords: Aspirin-exacerbated respiratory disease; Aspirin-induced asthma; Desensitization; Quality of life; Survey